Investors

Financial Reports

Access GENinCode’s full library of annual and interim reports, from the latest results to prior-year filings in one place.

Find Out More

Share Price & RNS

Track GENinCode’s latest live share price movements alongside key company RNS regulatory announcements for timely investor insights

Find Out More

Corporate News

Keep up with GENinCode’s latest corporate news, including business updates, milestones, and key announcements for stakeholders.

Find Out More

Investor Centre

Explore GENinCode plc’s investor centre for detailed corporate governance, significant shareholder data, board committees, and scheduled investor events.

Discover the investor centre

Directors

Matthew Walls

Chief Executive Officer

Mr Walls co-founded GENinCode in September 2018 and is the Group’s Chief Executive Officer. Between September 2018 and October 2019, he was also Chairman of Concepta plc (now MyHealthChecked plc), which he left to dedicate his time to GENinCode. Prior to that Mr Walls was CEO and Executive Chairman of Atlantis Healthcare, a leading international patient behavioural change company. Before joining Atlantis Healthcare, Mr Walls spent over eight years as CEO of the personalised medicine and molecular diagnostics company Epistem Holdings plc (now Genedrive plc), which he listed on AIM in 2017. He brings more than 30 years of senior leadership experience in leading, advising and developing public and private health care technology companies. Mr Walls started his career with ICI helping to lead its transition to AstraZeneca where he became Global Commercial Director and was commercially and financially responsible for strategy and international business operations. Mr Walls qualified as an accountant with ICI plc and studied at Manchester University.

Watch Video

Paul Foulger

Chief Financial Officer

Mr Foulger joined GENinCode in January 2021, becoming a director in April 2021. He is a seasoned CFO with substantial strategic, entrepreneurial, and commercial experience at Board level within both start-up biotech companies as well as large corporates. He has been CFO at NovaBiotics Ltd, Venn Life Sciences plc, PredictImmune Ltd, and Elsevier Science, amongst others. More recently he was Group CFO at EKF Diagnostics plc, the global point-of-care and central lab devices and tests medical manufacturer. He has experience in managing a broad range of corporate transactions including lead roles in a number of IPOs on the AIM market, two management buy-outs, over £100m of fund-raising and a number of acquisitions both in Europe and the US. He is currently a non-executive director of two UK-based companies, Autoclenz Ltd, an automotive services company, and Penrhos Bio Ltd, a company with innovative bioderived anti-biofilm technology. He obtained an MBA from Warwick Business School and is a qualified Certified Accountant.

Bill Rhodes

Independent Non-Executive Chairman

Mr Rhodes became Chairman of GENinCode in January 2021. He was Chairman of the Nasdaq-listed bioinformatics and genomic analysis company OpGen Inc. until its sale in 2024, was past Chairman of the supervisory board of the Dutch private company CytoSmart Technologies BV until their 2022 sale to Axion Biosystems, was a non-executive director and Interim Chairman of the AIM-listed in vitro diagnostic company Omega Diagnostics Group plc until he retired from their board after 9 years of service and was a board member of Paramit, a Californian-based private medical device contract manufacturer until their sale to Swiss medical products company Tecan in 2021. He was also, until 2024, a non-executive Board member of OncoDNA, a Belgium-based genomics testing company. He is also Senior Executive in Residence mentoring life science start-ups at Cornell University, with which he has been involved since 2013. Prior to his role at Cornell University, he spent 14 years at Becton, Dickinson & Co. (BD), one of the world’s leading suppliers of medical, diagnostic and life science research products. During his time at BD, he held a number of senior leadership positions most latterly as Senior Vice President, Corporate Strategy and Development, responsible for the group’s worldwide mergers and acquisitions and corporate strategies. Prior to the role, Mr Rhodes was Worldwide President of BD Biosciences, a business segment with turnover of over US$1.0 billion. Prior to working for BD, he held senior business development positions with Pfizer and J&J. He has a BSc in entomology from Cornell University and an MSc in International Business from Seton Hall University.

Sergio Olivero

Independent Non-Executive Director

Mr Oliveró was appointed a non-executive director of GENinCode in May 2020. Mr Oliveró is a veteran in the life sciences/healthcare industry with more than 30 years’ experience in diagnostics in Spain and Portugal, leading his own company Equipos Medico-Biológicos with a highly successful track record of medical device provision to the IVF market.

Felix Frueh

Non-Executive Director

Mr Frueh is a senior life sciences executive with over 25 years of experience setting scientific and corporate strategy in precision medicine, and has founded several start-ups in the diagnostics and pharmaceutical sectors. He worked in the regulatory space for 18 years, including five years with the FDA as the Agency’s first Assoc. Director for Genomics. Felix oversaw the world's largest next-generation, CLIA-certified, whole human genome sequencing laboratory as CSO of Human Longevity, served as President of Medco Research Institute, Res. Director for pharmacogenetics at Transgenomics, and Asst. Director of Protogene Laboratories. He is Co-Founder and CEO at PAGE Therapeutics and Founder and Executive Partner at Opus Three. He also co-founded and serves as CSO of Selva Therapeutics and co-founded and served as the CEO of Intellos Health. Felix received his PhD in biochemistry from the University of Basel in Switzerland and completed postdoctoral fellowships at the University of Basel and Stanford University. He has served as a consultant, strategic advisor, and Board member to numerous diagnostic, pharmaceutical, and other healthcare companies. The Board meets regularly to review, formulate, and approve the Group’s strategy, budgets, and corporate actions and oversee the Group’s progress towards its goals. In accordance with the best practice, the Company has established Audit, Remuneration and Nomination committees with formally delegated duties and responsibilities and with written terms of reference. Each of these committees will meet as and when appropriate, but at least twice each year. From time to time separate committees may be set up by the Board to consider specific issues when the need arises.

Jordi Puig

Chief Operations Officer

Mr Puig co-founded GENinCode in September 2018 and is the Group’s Chief Operating Officer. Prior to forming GENinCode, he worked for the Ferrer Group from 2006 through to 2018 where he was initially co-founder and CFO of the company’s personalised medicine division Gendiag.exe and then CEO of Ferrer inCode, the division from which the Company acquired its core products and technology in September 2018. He brings more than 20 years’ experience in pharmaceuticals, biotech and global strategic alliances and finance. He qualified as an accountant with Arthur Andersen.

Professor Huon Gray CBE

Independent Non-Executive Director

Professor Gray has 30 years’ experience practising as a consultant cardiologist for the NHS and private sector, with particular experience in cardiovascular risk assessment and interventional cardiology. Huon served as the National Clinical Director for Heart Disease in the Department of Health and then NHS England from 2012-2019, advising government, all party parliamentary groups, the NHS and NICE on healthcare delivery and reform. He is a former President of the British Cardiac Society (now the British Cardiovascular Society) and was previously Chair of the International Council of the American College of Cardiology. In 2014 Huon was awarded the Mackenzie Medal by the British Cardiovascular Society in recognition of his services to British cardiology, and made ‘Master’ by the American College of Cardiology in 2018. In 2019, he was awarded the CBE in the Queen’s New Year’s Honours List for his services to cardiology. Huon’s exposure to the US healthcare system through his work with the American College of Cardiology over 15 years, in roles such as Trustee and Chair of its Governance Committee, will support the Company as it targets the US as one of its primary markets. Additionally, during Huon’s tenure at NHS England, he acted as a liaison with industry and Academic Health Science Networks, helping deliver healthcare in the NHS through encouraging the adoption of innovation and new technology.

Investor Alert

Subscribe to our investor alert service and receive all press releases, financial results and other key shareholder messages as soon as they become available.

Please enter your name and email address in the box on the right, select Subscribe and click Submit to add your name to our list. You will receive an email confirming your registration.

This Email Alert service is provided by InvestorCom Limited (‘we’ or ‘us’) on behalf of GENinCode.

InvestorCom and GENinCode respect your privacy. We promise not to share, rent or sell the information we collect from you. Your data is stored securely.

You can unsubscribe at any time by entering your email address and selecting ‘Unsubscribe’ and pressing the Submit button.

Investors

Financial Reports

Share Price & RNS

Corporate News

Investor Centre